Record sale and strategic growth in the middle …

• Consolidated net turnover: USD 106.7 million, by 25% on a reported basis or 26% on a constant currency base from year to year.

• Full year 2025 net sales instructions: Readed from 475 to 485 million US dollars.

• US -glaucoma -franchise -net sales: USD 59.1 million, which corresponds to growth of 41% compared to the previous year.

• International Glaucom -Franchise -Netto sales: 29 million US dollars, with a growth of 15% based and 19% on constant currency base.

• Franchise -Netto sale of cornea health: $ 18.5 million.

• Cash and equivalent: Over 303 million US dollars without debt.

Appearance date: April 30, 2025

You can find the complete copy of the earnings call in the complete earnings call.

• The Glaucos Corp (NYSE: GKOS) reported consolidated net turnover in the first quarter in the first quarter of USD $ 106.7 million and marked an increase in the reported basis by 25% and 26% on a constant currency base compared to the previous year.

• The company confirmed the total annual turnover of $ 485 million, which confirmed the trust in its growth curia for its growth course in net sales sales preparation of $ 485 million.

• A strong performance was driven by the introduction of idosis and robust growth in both the USA and in international glaucoma franchise.

• The US glaucoma franchise achieved a net turnover of $ 59.1 million in the first quarter with growth of 41% compared to the previous year, mainly due to the success of idose tr.

• The Glaukos Corp (NYSE: GKOS) has a strong capital position with over 303 million US dollars of cash equivalents and without debts that enables a further investment in growth initiatives.

• The implementation of five Mac -LCDs at the end of 2024 caused market turbulence and has an impact on the use of two most important surgical devices in the same procedure, which is expected to continue in 2025.

• The company sees itself exposed to the examination of new competition products in large international markets from potential headwind.

• Due to the effects of MDRP, the franchise for corneal health had the challenges that influence the realized income.

• There are continuing uncertainties in relation to the global macroeconomic environment that could affect future performance.

• The company navigates the complex reimbursement dynamics for idosis TR with different progress in different Mac regions.

Q: Can you give growth in the US state and how doctors react to the LCD changes? A: Joseph Gilliam, President and COO, explained that the United States recorded over 40% compared to the previous year, which is due to Idosis TR, although LCD restrictions were brought to a decline in the MIGS franchise with medium-sized harmony. The doctors adapt to these restrictions and focus more on a serial approach to glaucoma supply.